- Home
- KLXE vs CMMB Comparison
KLXE vs CMMB Comparison
Compare KLXE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLXE
- CMMB
- Stock Information
- Founded
- KLXE 2018
- CMMB 2004
- Country
- KLXE United States
- CMMB Israel
- Employees
- KLXE N/A
- CMMB N/A
- Industry
- KLXE Oilfield Services/Equipment
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- KLXE Energy
- CMMB Health Care
- Exchange
- KLXE Nasdaq
- CMMB Nasdaq
- Market Cap
- KLXE 29.1M
- CMMB 23.6M
- IPO Year
- KLXE N/A
- CMMB N/A
- Fundamental
- Price
- KLXE $1.78
- CMMB $1.20
- Analyst Decision
- KLXE Hold
- CMMB Strong Buy
- Analyst Count
- KLXE 1
- CMMB 2
- Target Price
- KLXE $4.50
- CMMB $9.00
- AVG Volume (30 Days)
- KLXE 282.6K
- CMMB 167.2K
- Earning Date
- KLXE 05-08-2025
- CMMB 05-08-2025
- Dividend Yield
- KLXE N/A
- CMMB N/A
- EPS Growth
- KLXE N/A
- CMMB N/A
- EPS
- KLXE N/A
- CMMB N/A
- Revenue
- KLXE $709,300,000.00
- CMMB N/A
- Revenue This Year
- KLXE $2.03
- CMMB N/A
- Revenue Next Year
- KLXE $4.88
- CMMB N/A
- P/E Ratio
- KLXE N/A
- CMMB N/A
- Revenue Growth
- KLXE N/A
- CMMB N/A
- 52 Week Low
- KLXE $1.51
- CMMB $0.58
- 52 Week High
- KLXE $7.66
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- KLXE 31.63
- CMMB 50.27
- Support Level
- KLXE $1.64
- CMMB $1.08
- Resistance Level
- KLXE $1.93
- CMMB $1.25
- Average True Range (ATR)
- KLXE 0.29
- CMMB 0.11
- MACD
- KLXE 0.02
- CMMB 0.04
- Stochastic Oscillator
- KLXE 15.79
- CMMB 83.65
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.